At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 235 enrolled
Drug / intervention
exenatide +1 moredrug
Likely dose
exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone
In Brief
A Phase 3 clinical trial evaluating exenatide and insulin glargine for Type 2 Diabetes. Completed, enrolled 235 participants across 31 sites.
Detailed Summary
This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with minimum weight gain, in patients with uncontrolled type 2 diabetes on OADs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited Kingdom
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedAug 2006
Primary CompletionApr 2008
TodayJul 2026
First PostedAug 4, 2006
Enrollment StartJun 1, 2006
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.9 years ago
Interventions
exenatidedrug
subcutaneous injection, 5mcg or 10mcg, twice a day
insulin glarginedrug
subcutaneous injection, titrated to target blood glucose level, once a day